Compare RCG & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCG | AEON |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 19.0M |
| IPO Year | 1996 | N/A |
| Metric | RCG | AEON |
|---|---|---|
| Price | $3.01 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 4.6K | ★ 28.2K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.40 | $0.51 |
| 52 Week High | $3.31 | $1.45 |
| Indicator | RCG | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 66.33 | 44.17 |
| Support Level | $2.51 | $0.65 |
| Resistance Level | $3.31 | $0.75 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 85.42 | 79.34 |
RENN Fund Inc is a registered, non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with above-market rates of return through capital appreciation and income by a long-term, value oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities, including convertible and non-convertible debt securities or loans, distressed debt, warrants, preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. To a lesser extent, the fund sells short stocks, exchange-traded funds, and exchange-traded notes. It invests in various industries, including communication services, surgical and medical instruments, oil and gas, etc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.